Cargando…

Serum ceruloplasmin and the risk of cancer in Finland.

The relationship between serum ceruloplasmin level and cancer incidence was investigated in a case-control study nested within a longitudinal study of 39,268 Finns participating in the Social Insurance Institution's Mobile Clinic Health Examination Survey carried out in 1968-1972. During a medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Knekt, P., Aromaa, A., Maatela, J., Rissanen, A., Hakama, M., Aaran, R. K., Nikkari, T., Hakulinen, T., Peto, R., Teppo, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977734/
https://www.ncbi.nlm.nih.gov/pubmed/1739632
_version_ 1782135325653467136
author Knekt, P.
Aromaa, A.
Maatela, J.
Rissanen, A.
Hakama, M.
Aaran, R. K.
Nikkari, T.
Hakulinen, T.
Peto, R.
Teppo, L.
author_facet Knekt, P.
Aromaa, A.
Maatela, J.
Rissanen, A.
Hakama, M.
Aaran, R. K.
Nikkari, T.
Hakulinen, T.
Peto, R.
Teppo, L.
author_sort Knekt, P.
collection PubMed
description The relationship between serum ceruloplasmin level and cancer incidence was investigated in a case-control study nested within a longitudinal study of 39,268 Finns participating in the Social Insurance Institution's Mobile Clinic Health Examination Survey carried out in 1968-1972. During a median follow-up of 8 years, 766 cancer cases were identified. Ceruloplasmin levels were determined from stored serum samples collected at the baseline from these cancer cases and from two matched controls per case. The overall incidence of cancer was positively associated with serum ceruloplasmin level. The association was strongest for lung cancer and other cancers related to smoking and, consequently, in males. The smoking-adjusted relative risk of lung cancer among men was 4.3 (95% confidence interval (CI) = 1.8-10.6) in the highest quintile of serum ceruloplasmin as compared with that in the lowest quintile. The corresponding relative risks for cancers related to smoking combined, and for cancers not related to smoking were 3.9 (CI = 1.9-8.4) and 0.9 (CI = 0.6-1.5), respectively. The elevated risk of lung cancer at high concentrations of serum ceruloplasmin persisted after further adjustment for several potential confounding factors such as serum levels of vitamins A and E and selenium. The risk was stronger during the first 6 years of follow-up than later, and strongest during the first 2 years. The most likely explanation of the present results thus is that high serum ceruloplasmin levels in lung cancer are mainly due to occult cancer.
format Text
id pubmed-1977734
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19777342009-09-10 Serum ceruloplasmin and the risk of cancer in Finland. Knekt, P. Aromaa, A. Maatela, J. Rissanen, A. Hakama, M. Aaran, R. K. Nikkari, T. Hakulinen, T. Peto, R. Teppo, L. Br J Cancer Research Article The relationship between serum ceruloplasmin level and cancer incidence was investigated in a case-control study nested within a longitudinal study of 39,268 Finns participating in the Social Insurance Institution's Mobile Clinic Health Examination Survey carried out in 1968-1972. During a median follow-up of 8 years, 766 cancer cases were identified. Ceruloplasmin levels were determined from stored serum samples collected at the baseline from these cancer cases and from two matched controls per case. The overall incidence of cancer was positively associated with serum ceruloplasmin level. The association was strongest for lung cancer and other cancers related to smoking and, consequently, in males. The smoking-adjusted relative risk of lung cancer among men was 4.3 (95% confidence interval (CI) = 1.8-10.6) in the highest quintile of serum ceruloplasmin as compared with that in the lowest quintile. The corresponding relative risks for cancers related to smoking combined, and for cancers not related to smoking were 3.9 (CI = 1.9-8.4) and 0.9 (CI = 0.6-1.5), respectively. The elevated risk of lung cancer at high concentrations of serum ceruloplasmin persisted after further adjustment for several potential confounding factors such as serum levels of vitamins A and E and selenium. The risk was stronger during the first 6 years of follow-up than later, and strongest during the first 2 years. The most likely explanation of the present results thus is that high serum ceruloplasmin levels in lung cancer are mainly due to occult cancer. Nature Publishing Group 1992-02 /pmc/articles/PMC1977734/ /pubmed/1739632 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Knekt, P.
Aromaa, A.
Maatela, J.
Rissanen, A.
Hakama, M.
Aaran, R. K.
Nikkari, T.
Hakulinen, T.
Peto, R.
Teppo, L.
Serum ceruloplasmin and the risk of cancer in Finland.
title Serum ceruloplasmin and the risk of cancer in Finland.
title_full Serum ceruloplasmin and the risk of cancer in Finland.
title_fullStr Serum ceruloplasmin and the risk of cancer in Finland.
title_full_unstemmed Serum ceruloplasmin and the risk of cancer in Finland.
title_short Serum ceruloplasmin and the risk of cancer in Finland.
title_sort serum ceruloplasmin and the risk of cancer in finland.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977734/
https://www.ncbi.nlm.nih.gov/pubmed/1739632
work_keys_str_mv AT knektp serumceruloplasminandtheriskofcancerinfinland
AT aromaaa serumceruloplasminandtheriskofcancerinfinland
AT maatelaj serumceruloplasminandtheriskofcancerinfinland
AT rissanena serumceruloplasminandtheriskofcancerinfinland
AT hakamam serumceruloplasminandtheriskofcancerinfinland
AT aaranrk serumceruloplasminandtheriskofcancerinfinland
AT nikkarit serumceruloplasminandtheriskofcancerinfinland
AT hakulinent serumceruloplasminandtheriskofcancerinfinland
AT petor serumceruloplasminandtheriskofcancerinfinland
AT teppol serumceruloplasminandtheriskofcancerinfinland